|Articles|July 1, 2011

Applied Clinical Trials

  • Applied Clinical Trials-07-01-2011
  • Volume 20
  • Issue 7

Value of Time and Money

Industry Standard Research has recently released its 3rd annual "CRO Quality Benchmarking Report." The report not only profiles the delivery quality of leading CROs, but also provides a wealth of information that relates to larger industry trends, including the value of recruitment speed.

Industry Standard Research has recently released its 3rd annual "CRO Quality Benchmarking Report." The report not only profiles the delivery quality of leading CROs, but also provides a wealth of information that relates to larger industry trends, including the value of recruitment speed.

After three consecutive years of collecting data, a critical mass to reflect upon has been collected. The basic statistics class axiom: "It takes three data points to make a trend," has been met.

Source: ISR Reports: Survey participants were asked to indicate their preference for one benefit over the other. n=160 (2009); 150 (2010); 169 (2011)

After examining the data, it is clear and undeniable: sponsors are expressing an unmet need for faster recruitment. It's not difficult to make sense of this. Project manager job appraisals and compensation are tied to trial speed. In addition, the rule-of-thumb is that for each day's delay in getting a drug to market, the manufacturer loses a million dollars in revenue. Perhaps to some readers this qualifies as a "duh" take-away, but the magnitude of the disparity remains interesting—price is important too.

Patient recruitment continues to be a source of consternation in the industry, and service providers are constantly measured against this metric. The ones that do it well will establish loyalty among their customers and the ones that do it poorly will struggle.

—Industry Standard Research, www.ISRreports.com.

Articles in this issue


Related to this article

What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.